ArticleCase reports in oncological medicine2026
Dual Pathway Inhibition in Patients With mRCC: A Case Series From Kuwait Highlighting the Role of Avelumab and Axitinib.
Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual Pathway Inhibition in Patients With mRCC: A Case Series From Kuwait Highlighting the Role of Avelumab and Axitinib.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal cell carcinoma (RCC) accounts for approximately 3% of adult cancers and is characterized by aggressive behavior and early metastatic potential. The therapeutic paradigm of metastatic RCC (mRCC) has evolved from tyrosine kinase inhibitors (TKIs) alone to immune checkpoint inhibitors (ICIs) and ICI-TKI combinations. Avelumab, an anti-PD-L1 antibody, in combination with axitinib, a VEGFR-targeted TKI, has demonstrated efficacy in pivotal trials such as JAVELIN Renal 101. Objective: The objective of this study is to report the clinical outcomes of four patients with advanced mRCC and extensive metastases treated with avelumab with axitinib at the Kuwait Cancer Control Center (KCCC). Methods: This case series describes diagnostic imaging, treatment regimens, and disease progression in four patients. Imaging modalities included PET-CT and CT scans, performed at multiple intervals to assess therapeutic response, disease control, and treatment tolerability. Results: All patients demonstrated favorable radiological and clinical responses despite high metastatic burden and the presence of comorbidities, including disease regression or stable disease across multiple metastatic sites. Treatment was generally well tolerated, with no Grade III or IV toxicities recorded. Conclusion: This case series involving patients treated at KCCC demonstrates the real-world efficacy and tolerability of avelumab plus axitinib as a first-line option for metastatic renal cell carcinoma, even in patients with high metastatic burden, comorbidities, or prior treatment failure. Outcomes observed are consistent with JAVELIN Renal 101 trial findings, reinforcing the therapeutic value of dual immune and angiogenic pathway inhibition in advanced RCC care. Further investigation into biomarkers and patient selection may help optimize clinical outcomes across diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.